These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

333 related articles for article (PubMed ID: 25599347)

  • 1. Factors associated with lack of viral suppression at delivery among highly active antiretroviral therapy-naive women with HIV: a cohort study.
    Katz IT; Leister E; Kacanek D; Hughes MD; Bardeguez A; Livingston E; Stek A; Shapiro DE; Tuomala R
    Ann Intern Med; 2015 Jan; 162(2):90-9. PubMed ID: 25599347
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Time to viral load suppression in antiretroviral-naive and -experienced HIV-infected pregnant women on highly active antiretroviral therapy: implications for pregnant women presenting late in gestation.
    Aziz N; Sokoloff A; Kornak J; Leva NV; Mendiola ML; Levison J; Feakins C; Shannon M; Cohan D
    BJOG; 2013 Nov; 120(12):1534-47. PubMed ID: 23924192
    [TBL] [Abstract][Full Text] [Related]  

  • 3. HIV viraemia and mother-to-child transmission risk after antiretroviral therapy initiation in pregnancy in Cape Town, South Africa.
    Myer L; Phillips TK; McIntyre JA; Hsiao NY; Petro G; Zerbe A; Ramjith J; Bekker LG; Abrams EJ
    HIV Med; 2017 Feb; 18(2):80-88. PubMed ID: 27353189
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Factors associated with HIV RNA levels in pregnant women on non-suppressive highly active antiretroviral therapy at conception.
    European Collaborative Study
    Antivir Ther; 2010; 15(1):41-9. PubMed ID: 20167990
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Risk factors for detectable HIV-1 RNA at delivery among women receiving highly active antiretroviral therapy in the women and infants transmission study.
    Katz IT; Shapiro R; Li D; Govindarajulu U; Thompson B; Watts DH; Hughes MD; Tuomala R
    J Acquir Immune Defic Syndr; 2010 May; 54(1):27-34. PubMed ID: 20065861
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mode of Delivery among HIV-Infected Pregnant Women in Philadelphia, 2005-2013.
    Thompson DR; Momplaisir FM; Adams JW; Yehia BR; Anderson EA; Alleyne G; Brady KA
    PLoS One; 2015; 10(12):e0144592. PubMed ID: 26657902
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Factors associated with viral load suppression in HIV-infected pregnant women in Rio de Janeiro, Brazil.
    Joao EC; Gouvêa MI; Menezes JA; Sidi LC; Cruz ML; Berardo PT; Ceci L; Cardoso CA; Teixeira Mde L; Calvet GA; Matos HJ
    Int J STD AIDS; 2012 Jan; 23(1):44-7. PubMed ID: 22362687
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Low detectable postpartum viral load is associated with HIV transmission in Malawi's prevention of mother-to-child transmission programme.
    Landes M; van Lettow M; Nkhoma E; Tippett Barr B; Truwah Z; Shouten E; Jahn A; Auld A; Kalua T; van Oosterhout JJ
    J Int AIDS Soc; 2019 Jun; 22(6):e25290. PubMed ID: 31180186
    [TBL] [Abstract][Full Text] [Related]  

  • 9. When should HAART be initiated in pregnancy to achieve an undetectable HIV viral load by delivery?
    Read PJ; Mandalia S; Khan P; Harrisson U; Naftalin C; Gilleece Y; Anderson J; Hawkins DA; Taylor GP; de Ruiter A;
    AIDS; 2012 Jun; 26(9):1095-103. PubMed ID: 22441248
    [TBL] [Abstract][Full Text] [Related]  

  • 10. No perinatal HIV-1 transmission from women with effective antiretroviral therapy starting before conception.
    Mandelbrot L; Tubiana R; Le Chenadec J; Dollfus C; Faye A; Pannier E; Matheron S; Khuong MA; Garrait V; Reliquet V; Devidas A; Berrebi A; Allisy C; Elleau C; Arvieux C; Rouzioux C; Warszawski J; Blanche S;
    Clin Infect Dis; 2015 Dec; 61(11):1715-25. PubMed ID: 26197844
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of antiretroviral therapy on pregnancy outcome in HIV-1 positive women.
    Kowalska A; Niemiec T; El Midaoui A; Burkacka E
    Med Wieku Rozwoj; 2003; 7(4 Pt 1):459-68. PubMed ID: 15010556
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Factors associated with virological response in women receiving highly-active antiretroviral prophylaxis for HIV-1 mother-to-child transmission].
    Palacios R; Senise JF; Vaz MJ; Castelo A
    Enferm Infecc Microbiol Clin; 2008; 26(7):411-5. PubMed ID: 18842235
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The cost-effectiveness of directly observed highly-active antiretroviral therapy in the third trimester in HIV-infected pregnant women.
    McCabe CJ; Goldie SJ; Fisman DN
    PLoS One; 2010 Apr; 5(4):e10154. PubMed ID: 20405011
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Maternal HIV viral load testing during pregnancy and postpartum care in Gauteng Province, South Africa.
    Moyo F; Mazanderani AH; Kufa T; Sherman GG
    S Afr Med J; 2021 Apr; 111(5):469-473. PubMed ID: 34852890
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Viral suppression and factors associated with failure to achieve viral suppression among pregnant women in South Africa.
    Woldesenbet SA; Kufa T; Barron P; Chirombo BC; Cheyip M; Ayalew K; Lombard C; Manda S; Diallo K; Pillay Y; Puren AJ
    AIDS; 2020 Mar; 34(4):589-597. PubMed ID: 31821189
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Short communication: Use of raltegravir in late-presenting HIV-infected pregnant women.
    Nóbrega I; Travassos AG; Haguihara T; Amorim F; Brites C
    AIDS Res Hum Retroviruses; 2013 Nov; 29(11):1451-4. PubMed ID: 23731224
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prevention of mother-to-child HIV transmission: similar access for sub-Sahara African immigrants and for French women?
    Jasseron C; Mandelbrot L; Tubiana R; Teglas JP; Faye A; Dollfus C; Le Chenadec J; Rouzioux C; Blanche S; Warszawski J;
    AIDS; 2008 Jul; 22(12):1503-11. PubMed ID: 18614874
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Optimizing prevention of HIV mother to child transmission: Duration of antiretroviral therapy and viral suppression at delivery among pregnant Malawian women.
    Chagomerana MB; Miller WC; Tang JH; Hoffman IF; Mthiko BC; Phulusa J; John M; Jumbe A; Hosseinipour MC
    PLoS One; 2018; 13(4):e0195033. PubMed ID: 29614083
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Same-day antiretroviral therapy (ART) initiation in pregnancy is not associated with viral suppression or engagement in care: A cohort study.
    Langwenya N; Phillips TK; Brittain K; Zerbe A; Abrams EJ; Myer L
    J Int AIDS Soc; 2018 Jun; 21(6):e25133. PubMed ID: 29939483
    [TBL] [Abstract][Full Text] [Related]  

  • 20. High viral load and elevated angiogenic markers associated with increased risk of preeclampsia among women initiating highly active antiretroviral therapy in pregnancy in the Mma Bana study, Botswana.
    Powis KM; McElrath TF; Hughes MD; Ogwu A; Souda S; Datwyler SA; von Widenfelt E; Moyo S; Nádas M; Makhema J; Machakaire E; Lockman S; Essex M; Shapiro RL
    J Acquir Immune Defic Syndr; 2013 Apr; 62(5):517-24. PubMed ID: 23344545
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.